Margaret Dugan sold $27k of SDGR
Chief Medical Officer at Schrodinger, Inc.. 1,531 shares at an average of $17.78, traded Oct 15, 2024, filed Oct 16, 2024.
Score components
- +15RoleOfficer
- +5Trade size$27k at market
- +5Share of holdings soldSold 10% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +3.5%, 3m +7.7%, 6m +40.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001490978-24-000080, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 15, 2024 | SOpen-market sale Common Stock10b5-1 | -1,531 | $17.78 | $27k | 13,469 | Oct 16, 2024 |
Related signals
Other insiders at Schrodinger, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 14Weak | Schrodinger, Inc. | Karen Akinsanya See Remarks | $928k 31,599 shares | -31% | |
| 21Weak | Schrodinger, Inc. | Karen Akinsanya President of R&D, Therapeutics | $420k 16,723 shares | -52% | |
| 0Weak | Schrodinger, Inc. | Jenny Herman SVP & Controller | $14k 666 shares | -2% | |
| 13Weak | Schrodinger, Inc. | Robert Lorne Abel See Remarks | $32k 1,225 shares | -13% | |
| 3Weak | Schrodinger, Inc. | Jenny Herman SVP & Controller | $21k 859 shares | -5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.